Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F4co/AS01B therapeutic HIV vaccine study in ART-naive adults
2010-021356-26Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of F4co/AS01B in human immunodeficiency virus infection (HIV) (3 arms), sponsored by GSK. Primary endpoints: Change from baseline in HIV-1 viral load at Week 48 and Between-schedule comparison of HIV-1 viral load change at Week 48. Started Sep 2010; status: completed.
02
Drugs
F4co/AS01B
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2010-021356-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021356-26.